. 2020 Aug 4;7:466. doi: 10.3389/fmed.2020.00466
Copyright © 2020 Capochiani, Frediani, Iervasi, Paolicchi, Sani, Roncucci, Cuccaro, Franchi, Simonetti, Carrara, Bertaggia, Nasso, Riccioni, Scolletta, Valente, Conticini, Gozzetti and Bocchia.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Figure 2.
IL6 levels at baseline, after 24, 48, and 96 h from starting ruxolitinib treatment.